Physician profile
Harvinder Singh
NPI 1043267354
$19,956.90
in general payments reported to CMS, 2019-2025
58 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,817 · 2020: $854 · 2021: $6,772 · 2022: $1,006 · 2023: $2,388 · 2024: $1,300 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959 · Consulting Fee: $528 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.09 |
| Consulting Fee | $528.00 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,276.84 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Tesaro, INC. | $3,179.92 | 2019 | |
| Novocure INC. | $2,250.00 | 2021 | |
| Lilly USA, LLC | $1,950.57 | 2019-2024 | Retevmo, Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $1,103.19 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Athenex Pharmaceutical Division, LLC | $867.39 | 2019 | |
| Genentech USA, INC. | $659.53 | 2019-2023 | Lunsumio, Tecentriq, Venclexta |
| Tersera Therapeutics LLC | $555.72 | 2019-2023 | Zoladex |
| Daiichi Sankyo INC. | $539.32 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $459.55 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $453.14 | 2019-2025 | Tecvayli, Rybrevant, Darzalex |
| Abbvie INC. | $346.63 | 2019-2025 | Venclexta |
| Exelixis INC. | $342.68 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $302.72 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Asd Specialty Healthcare, LLC | $217.72 | 2019 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $214.42 | 2019-2025 | Trodelvy |
| Pfizer INC. | $213.47 | 2019-2025 | |
| Eisai INC. | $204.41 | 2019-2025 | |
| Seagen INC. | $186.60 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $179.05 | 2019-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $173.69 | 2019-2025 | |
| Astellas Pharma US INC | $170.84 | 2022-2025 | Xtandi, Padcev, Xospata |
| Clovis Oncology, INC. | $149.17 | 2019-2020 | |
| Amgen INC. | $135.44 | 2019-2023 | Xgeva, Vectibix, Lumakras |
| Celgene Corporation | $126.48 | 2019-2020 | |
| Array Biopharma INC | $123.97 | 2019-2023 | Xalkori, Lorbrena, Comirnaty |
| Takeda Pharmaceuticals U.S.A., INC. | $118.12 | 2019-2024 | Iclusig, Alunbrig, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $110.28 | 2019-2025 | |
| Inari Medical, INC. | $103.22 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Regeneron Healthcare Solutions, INC. | $96.70 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $93.14 | 2019-2024 | |
| Kite Pharma, INC. | $90.45 | 2022-2023 | Yescarta |
| Puma Biotechnology, INC. | $88.60 | 2019-2024 | |
| Foundation Medicine, INC. | $81.69 | 2019 | |
| Beone Medicines USA, INC. | $64.47 | 2025 | Brukinsa, Tevimbra |
| Organon LLC | $58.39 | 2022-2023 | Ontruzant, Renflexis |
| Alexion Pharmaceuticals, INC. | $53.23 | 2024-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $49.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $48.74 | 2020 | |
| Incyte Corporation | $47.81 | 2020-2025 | Zynyz, Monjuvi |
| Mirati Therapeutics, INC. | $41.60 | 2023 | Krazati |
| Taiho Oncology, INC. | $40.57 | 2019-2023 | |
| Agios Pharmaceuticals, INC. | $33.65 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $32.47 | 2024-2025 | |
| Pharmaessentia USA Corporation | $31.36 | 2024 | Besremi |
| Intuitive Surgical, INC. | $29.39 | 2025 | |
| Tempus Ai, INC | $29.03 | 2024 | Xt Cdx |
| Beigene USA, INC. | $25.46 | 2024 | Brukinsa |
| Blueprint Medicines Corporation | $24.46 | 2024 | Ayvakit |
| Dova Pharmaceuticals | $24.15 | 2019-2021 | |
| Immunogen, INC. | $23.87 | 2023 | Elahere |
| Adc Therapeutics America, INC. | $23.11 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.78 | 2023 | Monoferric |
| Sobi, INC | $19.32 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.20 | 2024 | Givlaari |
| Recordati_rare_diseases_inc. | $18.88 | 2024 | Sylvant |
| Myovant Sciences INC. | $16.75 | 2022 | |
| Heron Therapeutics, INC. | $16.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.